Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: MedImmune | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: MedImmune

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MedImmune

4Q Revenues: $492 million (+6%)

4Q Loss: $22 million (earnings were $50.5 million 4Q2004)

FY Revenues: $1.2 billion (+9%)

FY Loss: $17 million (loss of $3.8 million FY2004)

Comments: Worldwide sales of Synagis grew 13% to $1.1 billion for the year. Sales of FluMist decreased 56% for the year to $21 million and decreased 61% to $8 million for the quarter. R&D spending decreased 2% for the quarter to $117 million, and increased 27% for the year to $383 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters